Jim Tananbaum: A Great Figure in the Healthcare Industry

Jim Tananbaum is the CEO and founder of Foresite Capital, a company that deals in the provision of capital in the healthcare sector to upcoming healthcare leaders with the aim of improving patient care. Currently, Foresite Capital has over $1.2 billion in asset wealth. Also, it has invested in many other companies from therapeutics to diagnostics and so much more. Foresite Capital is based in San Francisco, and it also has a New York Office.

Jim Tananbaum has a strong academic background having graduated from prestigious universities around the United States pf America. Jim has graduated from the Harvard School of Business with an MBA & from Yale University with a BS in Electrical Engineering. Jim was also honored with an M. S from Massachusetts Institute of Technology (MIT) in the year 1985. He also has an MD from Harvard Medical School in the year 1989. Jim Tananbaum is also a three-time honoree in the Forbes Midas List.

According to Medium.com, before he founded Foresite Capital in 2011, Jim Tananbaum has also had founded leading biopharmaceutical companies. He is also the founder of GelTex Pharmaceuticals which has seen the bringing of two drugs to the market for less than $80 million. He founded GelTex in 1991 as he was finishing school. Currently, these drugs bring a lot of revenue. GelTex was later acquired for about 1.6 billion US dollars.

Jim Tananbaum was also the CEO and the starter of a pharmaceutical company, Theravence Inc. He also worked as a Senior Product Manager at a pharmaceutical company called Merck & Co., Inc. In summary, Jim Tananbaum has been a leader in the workforce of 21 successful companies with billions and multi-billions of income. Jim Tananbaum also has had Board and advisor roles in Jazz Pharmaceuticals where he is an investor.

Jim Tananbaum has been the major and the key leader in the decision making and investment strategies at Foresite Capital. Jim Tananbaum clearly has a lot of skills when it comes to startups and entrepreneurship based in the healthcare industry. This is as a result of his twenty-five years as a successful leader in major healthcare companies ranging from pharmaceuticals to healthcare providers. Check out his website: officialjimtananbaum.com

Ref: https://www.linkedin.com/in/jim-tananbaum-a7562a7/

Why the Best Publish in Oncotarget

Oncotarget, a peer review journal for oncologists, is one of the most highly-regarded peer review journals to be published in. Currently, this journal is sought out by those who are dedicated to the study of the cure for cancer, cancer prevention, new and innovative treatments, and areas of medicine and science that are related to the elderly population. This journal, started by Dr. Mikhail Blagosklonny, is also highly-regarded for its adherence to guidelines for best practices, as well as to ensuring that credit is given to whom it is due.

Regardless of whether or not the individual making a submission is an author, editor, or reviewer, they are all held to the standards of COPE, for the Conduct of Best Practices. This journal like many others gets hundreds of submissions, and its editors are required to review them one-by-one for their technical merit, quality of data, and the importance of the scientific community as well. Those who submit to this journal are free to do so regardless of their race, creed, color, or sexual orientation, adding to the professionalism an ability to raise the bar in all areas of its research and publications. Check the journal at SCImago Journal & Country Rank.

Dr. Mikhail Blagosklonny has been dedicated to cancer research, and the study of Rapamycin and its effects on cancer cells. The complexity of tumor development and other aspects of cancer research have made it the “go to” resource for those who wish to be expert researchers in cancer and related areas of medicine. This is another reason why Oncotarget continues to rise in popularity. This journal is dedicated to not only the study and prevention of cancer, but it is also committed to publishing the latest information regarding neuroscience, endocrinology, cardiology, cell biology, pharmacology and many other areas.

There are numerous authors that have made submissions to Oncotarget that have made viable contributions to the field of medicine, but also to the related research in related fields. Those who wish to read the latest on cancer research should take the time to read and research Oncotarget. Download output styles at Endnote.com